MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET

KALENDER, Ebuzer; DEMİR, Hasan Deniz; KARAOĞLAN, Hüseyin; ÇELEN, Y. Zeki; ELBOGA, UMUT; ŞAHİN, Ertan

MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET

Ebuzer KALENDER, (Gaziantep Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Gaziantep, Türkiye)

Hasan Deniz DEMİR, (Gaziantep Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Gaziantep, Türkiye)

Umut ELBOĞA, (Gaziantep Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Gaziantep, Türkiye)

Hüseyin KARAOĞLAN, (Gaziantep Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Gaziantep, Türkiye)

Ertan ŞAHİN, (Namık Kemal Üniversitesi, Nükleer Tıp Anabilim Dalı, Tekirdağ, Türkiye)

Y. Zeki ÇELEN (Gaziantep Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Gaziantep, Türkiye)

Bozok Tıp Dergisi

1 1

Yıl: 2014 Cilt: 4 Sayı: 3 Sayfa Aralığı: 14 - 18 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET

Öz:

Amaç: Çalışmanın amacı cerrahi sonrası yüksek kalsitonin seviyelerine sahip medüller tiroid karsinomlu (MTK)hastaların takibinde florodeoksiglikoz pozitron emisyon tomografisinin (FDG PET) etkinliğini değerlendirmektedir.Gereç ve Yöntemler: Çalışmaya yüksek kalsitonin seviyeleri nedeniyle kliniğimize FDG PET görüntüleme içinyönlendirilen MTK tanılı 6 hasta dahil edildi. Bütün hastalar erkekti. Yaş ortalaması 52±8 idi.Bulgular: Kalsitonin seviyeleri sırasıyla75 pg/ml, 90pg/ml, 94 pg/ml ve 127 pg/ml olan 4 hastada FDG PETgörüntülemede MTKnın rekürrens ya da metastazını düşündürecek bulgu izlenmedi. Kalsitonin seviyeleri1300 pg/ml ve 2110 pg/ml olan 2 hastada ise FDG PET bulguları pozitifti. Bu hastalarda lenf nodu ve kemikmetastazları saptandı.Tartışma: Öyle görünüyor ki MTKnın rutin görüntülemesinde FDG PETe yer yoktur. Ancak burada kalsitoninseviyeleri önem arz etmektedir. Kalsitonin seviyeleri 1000 pg/mlden yüksek hastalarda FDG PET oldukça faydalıolabilmekte ve birçok lezyon odağını tespit edebilmektedir. Ayrıca tüm vücut görüntülemeye olanak sağlamasıda önemli bir avantajıdır.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Hematoloji Tıbbi Laboratuar Teknolojisi

FDG PET in the Follow-up of Medullary Thyroid Carcinoma Patients

Öz:

Objective: The aim of study is to evaluate the impact of fluorodeoxyglucose positron emission tomography(FDG PET) in the follow-up of medullary thyroid carcionma (MTC) patients who had elevated calcitonin levelsafter surgery.Materials and Methods: Six patients diagnosed with MTC who referred to our clinic for FDG PET imagingbecause of the elevated calcitonin levels were included. All were male. Mean age was 52±8 years.Results: In 4 patients whose calcitonin levels were 75 pg/ml, 90pg/ml, 94 pg/ml and 127 pg/ml respectively,there was no evidence for recurrence or metastasis of MTC on FDG PET. FDG PET findings were positive in 2patients whose calcitonin levels were 1300 pg/ml and 2110 pg/ml respectively. In these patients lymph nodemetastases and bone metastases were detected.Conclusion: It seems that there is no place to FDG PET for routine imaging of MTC. But here calcitonin levels areimportant. In patients who have calcitonin levels higher than 1000 pg/ml FDG PET can be very useful and detecta lot of lesion foci. Also allowing to whole body imaging is a significant advantage of it.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Hematoloji Tıbbi Laboratuar Teknolojisi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91(9):1797808.
2. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299310.
3. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Non parallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):27885.
4. Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol. 2005;89(3):1229.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S, 1985-1995. Cancer. 1998;83(12):263848.
6. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol. 1991;7(2):929.
7. Bergholm U, Adami HO, Bergström R, Johansson H, Lundell G, Telenius-Berg M, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer. 1989;63(6):1196204.
8. Pitt SC, Moley JF. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol. 2010;37(6):567-79.
9. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):113948.
10. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M,et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):5017.
11. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005;12(4):25460.
12. Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 2008;33(2):6773.
13. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27(5):4906.
14. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001;28(11):16716.
15. De Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11(8):78694.
16. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28(1):6471.
17. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M,et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19(6):142534.
18. Aide N, Bardet S. Would patient selection based on both calcitonin blood level and doubling time improve 18F-FDG PET sensitivity in restaging of medullary thyroid cancer? J Nucl Med. 2007;48(9):1574-5.
19. Szakáll S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43(1):6671.
20. Koopmans KP, De Groot JW, Plukker JT, De Vries EG, Kema IP, Sluiter WJ, et al. Links TP. 18F Dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008; 49(4):52431.
21. Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET Imaging in Recurrent Medullary Thyroid Carcinoma. Int J Mol Imaging. 2012 Jul 18;2012:324686. doi: 10.1155/2012/324686.
22. Gotthardt M, Béhé MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33(11):12739.

APA	KALENDER E, DEMİR H, ELBOGA U, KARAOĞLAN H, ŞAHİN E, ÇELEN Y (2014). MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. , 14 - 18.
Chicago	KALENDER Ebuzer,DEMİR Hasan Deniz,ELBOGA UMUT,KARAOĞLAN Hüseyin,ŞAHİN Ertan,ÇELEN Y. Zeki MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. (2014): 14 - 18.
MLA	KALENDER Ebuzer,DEMİR Hasan Deniz,ELBOGA UMUT,KARAOĞLAN Hüseyin,ŞAHİN Ertan,ÇELEN Y. Zeki MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. , 2014, ss.14 - 18.
AMA	KALENDER E,DEMİR H,ELBOGA U,KARAOĞLAN H,ŞAHİN E,ÇELEN Y MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. . 2014; 14 - 18.
Vancouver	KALENDER E,DEMİR H,ELBOGA U,KARAOĞLAN H,ŞAHİN E,ÇELEN Y MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. . 2014; 14 - 18.
IEEE	KALENDER E,DEMİR H,ELBOGA U,KARAOĞLAN H,ŞAHİN E,ÇELEN Y "MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET." , ss.14 - 18, 2014.
ISNAD	KALENDER, Ebuzer vd. "MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET". (2014), 14-18.

APA	KALENDER E, DEMİR H, ELBOGA U, KARAOĞLAN H, ŞAHİN E, ÇELEN Y (2014). MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. Bozok Tıp Dergisi, 4(3), 14 - 18.
Chicago	KALENDER Ebuzer,DEMİR Hasan Deniz,ELBOGA UMUT,KARAOĞLAN Hüseyin,ŞAHİN Ertan,ÇELEN Y. Zeki MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. Bozok Tıp Dergisi 4, no.3 (2014): 14 - 18.
MLA	KALENDER Ebuzer,DEMİR Hasan Deniz,ELBOGA UMUT,KARAOĞLAN Hüseyin,ŞAHİN Ertan,ÇELEN Y. Zeki MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. Bozok Tıp Dergisi, vol.4, no.3, 2014, ss.14 - 18.
AMA	KALENDER E,DEMİR H,ELBOGA U,KARAOĞLAN H,ŞAHİN E,ÇELEN Y MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. Bozok Tıp Dergisi. 2014; 4(3): 14 - 18.
Vancouver	KALENDER E,DEMİR H,ELBOGA U,KARAOĞLAN H,ŞAHİN E,ÇELEN Y MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET. Bozok Tıp Dergisi. 2014; 4(3): 14 - 18.
IEEE	KALENDER E,DEMİR H,ELBOGA U,KARAOĞLAN H,ŞAHİN E,ÇELEN Y "MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET." Bozok Tıp Dergisi, 4, ss.14 - 18, 2014.
ISNAD	KALENDER, Ebuzer vd. "MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET". Bozok Tıp Dergisi 4/3 (2014), 14-18.